|Table of Contents|

Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced pulmonary sarcomatoid carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 20
Page:
3891-3896
Research Field:
Publishing date:

Info

Title:
Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced pulmonary sarcomatoid carcinoma
Author(s):
SHI Yanhui1; GAO Liwei1; WANG Junwei2
1.Department of Oncology；2.Department of Radiology,General Hospital of Pingmei Shenma Medical Group,Henan Pingdingshan 467000,China.
Keywords:
pulmonary sarcomatoid carcinoma; PD-1 inhibitor; immune checkpoint inhibitors (ICIs); targeted therapy; chemotherapy
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.20.013
Abstract:
Objective:To analyze the efficacy and prognostic factors of PD-1 inhibitors in advanced pulmonary sarcomatoid carcinoma.Methods:The survival rate and prognostic factors of 53 patients with advanced pulmonary sarcomatoid carcinoma，who had complete follow-up data，were retrospectively assessed by Kaplan-Meier analysis and multivariate regression analysis.Descriptive statistical methods were used to analyze the clinical and treatment characteristics of the patients,and qualitative data were described by the number of cases (n) and rate (%).Results:The objective response rate (ORR) and disease control rate (DCR) of 53 patients at 2 months after receiving immunotherapy were 32.1% and 83.0%,respectively.The ORR and DCR in the PD-1 inhibitor combination group were higher than those in the PD-1 inhibitor monotherapy group (P＜0.05).The DCRs of the PD-1 inhibitor plus targeted therapy group at 2 and 6 months were 88.9% and 50.0%,respectively,while the DCRs at 2 and 6 months of the PD-1 inhibitor plus chemotherapy group were 89.2% and 85.7%,respectively.The median progression-free survival (mPFS) of the 53 participants was 7.7 months,and the median overall survival (mOS) was 17.8 months.The mPFS and mOS of the PD-1 inhibitor plus targeted therapy group and PD-1 inhibitor plus chemotherapy group were higher than those of PD-1 inhibitor monotherapy group (6 vs 2.4 months,P＜0.001,16.2 vs 8.7 months,P＜0.001;8 vs 2.4 months,P＜0.001,19.7 vs 8.7 months,P＜0.001,respectively).Eastern Cooperative Oncology Group (ECOG) performance status (PS) score，MET exon14 skipping,and treatment options were independent prognostic factors for PFS.ECOG PS score,MET exon14 skipping,brain metastases,and treatment options were independent prognostic factors for OS.Conclusion:For patients with advanced pulmonary sarcomatoid carcinoma,PD-1 inhibitor combined with chemotherapy or targeted therapy is more effective than immunomonotherapy.The effect of PD-1 inhibitor combined with chemotherapy is more obvious in the early disease control rate,providing new ideas for the future application of immune and chemotherapy of advanced pulmonary sarcomatoid carcinoma.

References:

［1］ SUN L,DAI J,CHEN Y,et al.Pulmonary sarcomatoid carcinoma:experience from SEER database and Shanghai pulmonary hospital［J］.Ann Thorac Surg,2020,110(2):406-413.
［2］ NICHOLSON AG,TSAO MS,BEASLEY MB,et al.The 2021 WHO classification of lung tumors:impact of advances since 2015［J］.J Thorac Oncol,2022,17(3):362-387.
［3］ LI X,WU D,LIU H,et al.Pulmonary sarcomatoid carcinoma:progress,treatment and expectations［J］.Ther Adv Med Oncol,2020,12:1758853920950207.
［4］ DOMBLIDES C,LEROY K,MONNET I,et al.Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma［J］.J Thorac Oncol,2020,15(5):860-866.
［5］ YENDAMURI S,CATY L,PINE M,et al.Outcomes of sarcomatoid carcinoma of the lung:a surveillance,epidemiology,and end results database analysis［J］.Surgery,2012,152(3):397-402.
［6］ DAI G,HE L,YAN Q,et al.Case report:Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment［J］.Front Oncol,2023,13:1167516.
［7］ GU L,WEI X,ZHANG Z,et al.Treatment response to immunotherapy after crizotinib resistance in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation:a case report［J］.Clin Med Insights:Oncology,2022,16:11795549211067185.
［8］ MANEENIL K,XUE Z,LIU M,et al.Sarcomatoid carcinoma of the lung:the Mayo clinic experience in 127 patients［J］.Clin Lung Cancer,2018,19(3):e323-e333.
［9］ WEI Jingwen,HAO Yue,XIANG J,et al.The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma:A multicenter retrospective study［J］.Neoplasma,2022,69(6):1437.
［10］ MEHRAD M,ROY S,LAFRAMBOISE WA,et al.KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma［J］.Histopathology,2018,73(2):207-214.
［11］ LEE J,LA CHOI Y,JUNG HA,et al.Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma［J］.Eur J Cancer B Oral Oncol,2020,132:150-158.
［12］ SAFFROY R,FALLET V,GIRARD N,et al.MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung［J］.Oncotarget,2017,8(26):42428.
［13］ DONG Y,XU J,SUN B,et al.MET-targeted therapies and clinical outcomes:A systematic literature review［J］.Mol Diagn Ther,2022,26(2):203-227.
［14］ LI Y,GAO L,MA D,et al.Identification of MET exon14 skipping by targeted DNA-and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas［J］.Lung Cancer,2018,122:113-119.
［15］ ZHOU F,GUO H,ZHOU X,et al.Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma:a multicentric real-world study［J］.Ther Adv Med Oncol,2022,14:17588359221136759.
［16］ 熊伟杰,张新星,黄媚娟,等.32 例晚期及术后复发肺肉瘤样癌患者的治疗及生存分析［J］.四川大学学报:医学版,2014,45(2):320-323. XIONG WJ,ZHANG XX,HUANG MJ,et al.Outcomes of treatment of 32 cases of advanced or relapsed post-surgery pulmonary sarcomatoid carcinoma［J］.Journal of Sichuan University:Medical edition,2014,45(2):320-323.
［17］ 顾海艇,周建娅,吴挺,等.肺肉瘤样癌患者的临床特征及预后分析［J］.中华医学杂志,2018,98(10):744-748. GU HT,ZHOU JY,WU T,et al.Clinical features and prognosis of pulmonary sarcomatoid carcinoma［J］.National Medical Journal of China,2018,98(10):744-748.
［18］ 刘颖.基于 SEER 数据库的肺肉瘤样癌预后因素分析及生存预测模型建立［D］.大连：大连医科大学,2021. LIU Y.Analysis of prognostic factors and establishment of survival prediction model of pulmonary sarcomatoid carcinoma based on SEER database［D］.Dalian：Dalian Medical University,2021.
［19］ ZHAO C,GAO S,XUE Q,et al.Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma［J］.J Thorac Dis,2022,14(10):3773.
［20］ 李文宇,李灵常,霍介格.免疫检查点抑制剂的毒副作用及其管理［J］.世界华人消化杂志,2020,28(16):755-764. LI WY,LI LC,HUO JG.Side effects and management in immunotherapy based on immune checkpoint inhibitors［J］.World Chinese Journal of Digestology,2020,28(16):755-764.

Memo

Memo:
-
Last Update: 1900-01-01